Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI) has announced the promotion of Sohanya Cheng to Chief Commercial Officer, effective immediately. Cheng's role includes directing the company's commercial strategy, particularly the ongoing commercialization of XPOVIO® (selinexor). With 18 years of experience in oncology and significant contributions to Karyopharm's revenue increase in 2021, her leadership is anticipated to strengthen the company’s market position. Karyopharm continues to focus on expanding its oncology portfolio and preparing for forthcoming clinical trial results.

Karyopharm Therapeutics (Nasdaq: KPTI) reported preliminary unaudited net product revenues of approximately $29.7 million for Q4 2021 and $98.3 million for the full year. The company is focused on advancing its pipeline with upcoming results from the Phase 3 SIENDO study for selinexor in advanced endometrial cancer expected this quarter. Karyopharm aims to increase sales and adoption of XPOVIO in multiple myeloma and has partnered with Menarini for further commercialization. Notable 2021 achievements include gaining conditional marketing authorization in Europe and the UK for NEXPOVIO.

Karyopharm Therapeutics (Nasdaq: KPTI), a leader in cancer therapies, announced that CEO Richard Paulson will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 3:45 p.m. ET. There will be a Q&A session at 4:05 p.m. ET. The presentation will be held virtually, and a live webcast, along with presentation slides, will be available on the company’s investor website for 30 days post-event. Karyopharm specializes in innovative treatments targeting nuclear export for cancer and other diseases.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 5,600 shares to two new employees, effective December 31, 2021. The options, priced at $6.43 per share, are part of an inducement package compliant with Nasdaq Listing Rule 5635(c)(4). Each option vests over four years, with a portion vesting upon the one-year employment anniversary. Immediate exercise is possible upon termination for good reason or without cause within a year of a change in control. Karyopharm focuses on developing innovative cancer therapies, notably XPOVIO®, for various malignancies.

Karyopharm Therapeutics (KPTI) has entered an exclusive licensing agreement with Menarini Group to commercialize NEXPOVIO (selinexor) across Europe and other global territories. In exchange, Karyopharm will receive a $75 million upfront payment and be eligible for up to $202.5 million in future milestones, plus royalties on net sales. NEXPOVIO is conditionally authorized in the EU for treating multiple myeloma patients who have undergone at least four prior therapies. The partnership aims to enhance patient access to this innovative cancer therapy.

Karyopharm Therapeutics (Nasdaq: KPTI) has signed an exclusive licensing agreement with Menarini Group for the commercialization of NEXPOVIO (selinexor) in Europe and other regions. Karyopharm will receive an upfront payment of $75 million and potential milestones of up to $202.5 million, plus royalties on sales. NEXPOVIO, already authorized in the EU for treating multiple myeloma, may expand to additional oncology indications. This partnership aims to enhance patient access to innovative cancer treatments across key global markets.

Karyopharm Therapeutics (KPTI) announced that its partner, Antengene Corporation, received conditional approval from China's NMPA for XPOVIO (selinexor) in combination with dexamethasone for relapsed or refractory multiple myeloma patients. This approval follows positive results from the Phase 2 STORM trial and Antengene's Phase 2 MARCH trial in China. The Phase 3 BENCH trial will serve as a confirmatory trial. CEO Richard Paulson highlighted the significance of this approval in providing new treatment options for patients. Karyopharm remains focused on expanding XPOVIO's availability globally.

Karyopharm Therapeutics (Nasdaq: KPTI) presented updated data from the Phase 2 ESSENTIAL study on selinexor for myelofibrosis patients at the ASH 2021 Annual Meeting. Results revealed that 40% of patients achieved a spleen volume reduction (SVR) of at least 35%, and 60% experienced an SVR of at least 25% after 24 weeks of treatment. The drug exhibited a favorable safety profile with manageable side effects. Additionally, the company has initiated a new Phase 2 study comparing selinexor to physician's choice in previously treated myelofibrosis patients.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the appointment of Peter K Honig, MD, MPH, to its Board of Directors effective December 3, 2021. Dr. Honig brings over 30 years of experience in drug development from leadership roles at Pfizer, Merck, and the FDA. He replaces Mikael Dolsten, who stepped down on December 2, 2021, due to competing demands. Dr. Honig expressed enthusiasm for contributing to Karyopharm's growth and advancing its cancer therapies. The company is focused on pioneering novel cancer treatments, including its lead drug, XPOVIO®.